NVIDIA Company NASDAQ: NVDA is the undisputed leader of the artificial intelligence (AI) revolution. The company envisioned the future of artificial intelligence more than 12 years ago and began executing a plan for dominance. Because of this proven foresight and execution, investors pay close attention when NVIDIA sees an opportunity and invests its own money in promising artificial intelligence companies.
Here are two computer and technology stocks that NVIDIA has invested in that could be attractive to your portfolio.
Recursion Pharmaceuticals: AI-powered drug discovery center
Bringing a drug to market from discovery to US FDA approval can take more than 15 years and cost $2.5 billion. Completing the initial arduous task of drug discovery can take months to a year. Up to 90% of all drug candidates typically fail in clinical trials after spending millions of dollars.
Recursion Pharmaceuticals Inc. NASDAQ: RXRX accelerates the drug discovery process by using artificial intelligence, automated biology, and high-throughput screening and machine learning algorithms to identify and predict the effectiveness of potential drug targets. NVIDIA has invested $50 million in Recursion to accelerate the development of artificial intelligence models for drug discovery.
A universe of recursive data enables millions of wet-lab experiments to be conducted each week
Recursion Pharmaceuticals today
Recursion Pharmaceuticals
(As of 12/02/2024 6:02 PM ET)
- 52 week range
- $5.60
▼
$15.74
- Target price
- $9.25
Recursion’s massive, proprietary database of chemical and biological data, called the Recursions Data Universe, spans more than 23 petabytes and includes data on proteins, genes and pathways associated with disease. Its recursion map consists of hundreds of billions of searchable chemical and biological inferences, enabling millions of wet laboratory experiments to be performed each week.
Recursion can assess potential drug failure much earlier, saving millions of dollars and bringing drugs to market faster and more efficiently. Recursion partners with Bayer and Roche Holding AG OTsMCTs: RHHBI.
Recursion has five clinical trials underway and hopes to increase that number to 10 by acquiring a competitor for $688 million. Expertise PLS NASDAQ: EXAI. Exscientia has partnerships with Sanofi NASDAQ: SNY and Merck KGaA from Germany. New investors in Recursion stock will get both companies for the price of one. A merger is an all-stock transaction.
Recursion Pharmaceutical R&D Director Najat Khan commented: “The combination of Recursion and Exscientia is extremely complementary in terms of end-to-end exploitation of discoveries from biology to chemistry. It allows you to make medicine better and faster, and that’s what we’re trying to do.”
Serv Robotics: Delivering Takeout Food to an Area Near You
Serve Robotics Today
(As of 12/02/2024, 6:00 pm ET)
- 52 week range
- US$1.77
▼
$24.09
- Target price
- US$16.00
Food delivery is evolving from humans to delivery robots. Serv Robotics Inc. NASDAQ: SERV develops and operates autonomous, self-driving sidewalk delivery robots powered by artificial intelligence. In 2021, they were spun off from delivery service PostMates after being acquired Uber Technologies Inc. New York Stock Exchange: UBER. Uber is not only an investor, but also a partner and a customer.
Serv Robotics has struck a deal with Uber Eats to deploy 2,000 autonomous, AI-powered curbside delivery robots in 2025. Serv will not sell Serve robots, but will actually operate a fleet of delivery vehicles. Serve Robots currently only operates in Los Angeles, California, but is expected to begin shipping in Dallas, Texas. The company also announced a deal with Shake Shack Inc. NYSE: SHAK for delivery services. In April 2024, NVIDIA invested $3.7 million in the company through convertible notes.
Becoming a third generation service robot in partnership with Wing Aviation
The third generation robots are equipped with the NVIDIA Jetson Orin module, providing 5 times more calculations. Ouster Inc. New York Stock Exchange: EXIT upgraded sensors and LiDAR, larger cargo areas and smoother suspension, improved water resistance and 40% faster emergency braking. The company is also partnering with autonomous drone delivery service Wing for long-distance deliveries exceeding five miles. Servo robots can hand off deliveries to Wing’s flying drones to complete deliveries five to six miles away. Because drones fly in a straight line through the air, avoiding traffic, deliveries are much faster. Serve robots pay for themselves within a year or operations.
In addition to delivery, robots work inside the restaurant
Serve Robotics has acquired kitchen robot company Vebu, which created the Autocado robot used by Chipotle Mexican Grill Inc. New York Stock Exchange: CMG prepare guacamole. Chipotle produces more than 100 million pounds of guacamole annually. This acquisition takes Serv one step closer to becoming a one-stop supplier of restaurant automation technologies that enable restaurant automation and food delivery automation.
Full reimbursement for each robot within 12 months
Service robots complete deliveries in Los Angeles with a 99% completion rate. Serve will have 250 robots by the end of 2024, and 2,000 robots deployed by 2025. Full reimbursement for each robot is expected to occur within 12 months. Serve also outsources the production of its robots. Magna International Inc. New York Stock Exchange:.
Serve Robotics CEO Dr. Ali Kashani commented: “Regarding our agreement with Uber Eats to deploy 2,000 robots by the end of 2025, we are ahead of schedule with initial production and deployment. We continue to plan to deploy 2,000 new robots across multiple markets. next year.”
Kashani concludes, “In addition, we announced the potential acquisition of Vebu, which positions us in a strategically adjacent service offering, and we have initiated partnerships with Wing Aviation and Shack Shak to expand our footprint. Importantly, we successfully raised $32.3 million in new capital to provide financial flexibility and fund our expansion plans.”
Before you consider Recursion Pharmaceuticals, you need to hear this.
MarketBeat tracks Wall Street’s top-rated and best-performing analysts daily and the stocks they recommend to their clients. MarketBeat identified five stocks that top analysts are quietly whispering to their clients to buy now, before the broader market catches on… and Recursion Pharmaceuticals wasn’t on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, the top-rated analysts think these five stocks are Outperform Buys.
View five stocks here
Do you expect global energy demand to decline?! If not, then it’s time to take a look at what role energy stocks can play in your portfolio.
Get this free report